Sinaptica Therapeutics™
Sinaptica Therapeutics™ has developed a breakthrough personalized closed-loop neuromodulation therapy for Alzheimer’s Disease that works by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory.
Overview
Sinaptica Therapeutics is a clinical-stage company in the neuromodulation sector, headquartered in Cambridge, MA. The company has developed a personalized closed-loop neuromodulation therapy specifically for Alzheimer’s Disease (AD). Its SinaptiStim™ System enhances neuroplasticity through neurostimulation of key brain networks involved in memory. Sinaptica Therapeutics was founded by two clinical researchers specializing in noninvasive brain modulation for neurodegenerative disorders, with support from industry executives in biotech, digital health, and medical devices. The company has received FDA Breakthrough Designation based on significant Phase 2 clinical trial data that met all four gold-standard cognitive and functional endpoints. Sinaptica Therapeutics is leveraging over a decade of research in brain targeting methods and machine learning to advance personalized precision electromagnetic therapeutics, with multiple pending patents protecting its innovations.
Details
- Category
- Medical Equipment Manufacturing
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2021
- Followers
- 3,249
- Locations
- 245 First Street 18th Floor Cambridge, MA 02142, US
10250 Constellation Blvd Los Angeles, California 90067, US
Funding
Total rounds: 2
Last round: Convertible note, Jul 3, 2025